MAC
NVO

Mason & Associates (California)’s Novo Nordisk NVO Stock Holding History

Mason & Associates (California)’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,060
Closed -$245K – 116
2024
Q3 		$245K Buy
+2,060
New +$275K 0.06% 101

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Mason & Associates (California)'s NVO Position: Q4 2024 in Review

Mason & Associates (California) sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 2,060 shares — an estimated $245K sold.

Mason & Associates (California) first reported a position in NVO in Q3 2024 and held it in 1 quarter. The position peaked at $245K in Q3 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Mason & Associates (California) reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Mason & Associates (California) sold 2,060 Novo Nordisk shares in Q4 2024, an estimated $245K.
  • Mason & Associates (California) first reported a position in Novo Nordisk in Q3 2024 and held it in 1 quarter.
  • Mason & Associates (California)'s Novo Nordisk position peaked at $245K in Q3 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Mason & Associates (California)'s 13F filing for Q4 2024, filed 14 Jan 2025.